- Home
- CDNA
CDNA
CareDx Inc.
as 07-26-2024 4:00pm EST
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.
Upcoming Earnings Alert:
Get ready for potential market movements as CareDx Inc. CDNA prepares to release earnings report on 31 Jul 2024.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | BRISBANE |
| Market Cap: | 944.1M | IPO Year: | 2014 |
| Target Price: | $17.75 | AVG Volume (30 days): | 594.6K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.80 - $19.58 | Next Earning Date: | 07-31-2024 |
| Revenue: | $275,111,000 | Revenue Growth: | -13.93% |
| Revenue Growth (this year): | 1.53% | Revenue Growth (next year): | 6.83% |
Latest CareDx Inc. News
CDNA Breaking Stock News: Dive into CDNA Ticker-Specific Updates for Smart Investing
Business Wire
11 days ago
CareDx to Report Second Quarter 2024 Financial Results
Business Wire
2 months ago
Landmark Independent Publication in Nature Medicine Validates CareDx AlloView AI-Enabled Risk Prediction Model and Demonstrates AlloSure Kidney Detects Subclinical Rejection in Stable Patients
Business Wire
2 months ago
AI Integration and Real-World Utility of CareDx Portfolio Highlighted in New Data at the 2024 American Transplant Congress
Business Wire
2 months ago
CareDx Reiterates Position that it Does Not Infringe the ‘544 Patent, Injunction Motion is Irrelevant
Business Wire
2 months ago
CareDx to Participate in Upcoming Investor Conferences
Business Wire
2 months ago
Landmark Study Shows CareDx’s HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer Biopsies
MT Newswires
2 months ago
--Raymond James Downgrades CareDx to Market Perform From Outperform
MT Newswires
2 months ago
Stephens Adjusts Price Target on CareDx to $18 From $15, Maintains Overweight Rating
Compare CDNA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CDNA CareDx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.